PubMed:33161369
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 37-40 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
T2 | 45-48 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T3 | 139-147 | Body_part | denotes | Antibody | http://purl.org/sig/ont/fma/fma62871 |
T4 | 503-506 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
T5 | 511-514 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T6 | 567-575 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T7 | 686-689 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
T8 | 706-709 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T9 | 733-738 | Body_part | denotes | serum | http://purl.org/sig/ont/fma/fma63083 |
T10 | 772-777 | Body_part | denotes | serum | http://purl.org/sig/ont/fma/fma63083 |
T11 | 910-913 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
T12 | 1067-1070 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
T13 | 1099-1102 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
T14 | 1259-1262 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T15 | 1435-1438 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T16 | 1534-1537 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T17 | 1662-1665 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T18 | 1759-1762 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
T19 | 1829-1832 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
T20 | 1995-1998 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
T21 | 2003-2006 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 733-738 | Body_part | denotes | serum | http://purl.obolibrary.org/obo/UBERON_0001977 |
T2 | 772-777 | Body_part | denotes | serum | http://purl.obolibrary.org/obo/UBERON_0001977 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 81-89 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T2 | 229-237 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T3 | 264-272 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 492-500 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T5 | 600-608 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T6 | 724-732 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T7 | 899-907 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T8 | 1248-1256 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T9 | 1506-1515 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T10 | 1777-1785 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T11 | 1963-1971 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T12 | 1974-1983 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T13 | 2055-2063 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 148-155 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T2 | 156-159 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T3 | 427-437 | http://purl.obolibrary.org/obo/BFO_0000030 | denotes | OBJECTIVES |
T4 | 875-879 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
T5 | 1000-1003 | http://purl.obolibrary.org/obo/CLO_0053799 | denotes | 4-5 |
T6 | 1016-1020 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
T7 | 1128-1131 | http://purl.obolibrary.org/obo/CLO_0053799 | denotes | 4-5 |
T8 | 1368-1371 | http://purl.obolibrary.org/obo/CLO_0053799 | denotes | 4-5 |
T9 | 1384-1388 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
T10 | 1517-1518 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T11 | 1675-1678 | http://purl.obolibrary.org/obo/CLO_0001313 | denotes | 3-6 |
T12 | 1844-1849 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tests |
T13 | 1936-1940 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
T14 | 1961-1962 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T15 | 2040-2041 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
2 | 81-89 | Disease | denotes | COVID-19 | MESH:C000657245 |
3 | 90-98 | Species | denotes | patients | Tax:9606 |
19 | 229-239 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
20 | 264-272 | Disease | denotes | COVID-19 | MESH:C000657245 |
21 | 492-502 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
22 | 600-608 | Disease | denotes | COVID-19 | MESH:C000657245 |
23 | 609-617 | Species | denotes | patients | Tax:9606 |
24 | 724-732 | Disease | denotes | COVID-19 | MESH:C000657245 |
25 | 899-909 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
26 | 1248-1258 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
27 | 1506-1515 | Disease | denotes | infection | MESH:D007239 |
28 | 1560-1568 | Species | denotes | patients | Tax:9606 |
29 | 1638-1645 | Species | denotes | patient | Tax:9606 |
30 | 1777-1787 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
31 | 1923-1931 | Species | denotes | patients | Tax:9606 |
32 | 1963-1983 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
33 | 2055-2063 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-126 | Sentence | denotes | Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect. |
T2 | 127-138 | Sentence | denotes | BACKGROUND: |
T3 | 139-273 | Sentence | denotes | Antibody testing has recently emerged as an option to assist with determining exposure to SARS-CoV-2, the causative agent of COVID-19. |
T4 | 274-426 | Sentence | denotes | Elucidation of the kinetics and duration of the humoral response is important for clinical management and interpreting results from serological surveys. |
T5 | 427-438 | Sentence | denotes | OBJECTIVES: |
T6 | 439-618 | Sentence | denotes | Here we evaluated the clinical performance of Abbott SARS-CoV-2 IgM and IgG assays, as well as the longitudinal dynamics of the antibody response in symptomatic COVID-19 patients. |
T7 | 619-644 | Sentence | denotes | STUDY DESIGN AND RESULTS: |
T8 | 645-749 | Sentence | denotes | The diagnostic specificity was 100 % for IgM and 99.67 % for IgG using 300 pre-COVID-19 serum specimens. |
T9 | 750-1034 | Sentence | denotes | Using 1349 sequential serum samples collected up to 168 days post symptom onset from 427 PCR-confirmed individuals, clinical test sensitivity of the SARS-CoV-2 IgM assay was 24.6 % at ≤7 days, 75.3 % at 8-14 days, 95.0 % at 15-21 days, and 96.0 % at 4-5 weeks (peak test sensitivity). |
T10 | 1035-1098 | Sentence | denotes | The median duration of time for IgM seroconversion was 10 days. |
T11 | 1099-1212 | Sentence | denotes | IgM levels declined steadily 4-5 weeks after symptom onset, and the positive rate dropped to 30.8 % at >3 months. |
T12 | 1213-1402 | Sentence | denotes | The diagnostic sensitivity for the SARS-CoV-2 IgG assay post symptom onset was 23.2 % at ≤7 days, 69.5 % at 8-14 days, 93.6 % at 15-21 days, and 99.6 % at 4-5 weeks (peak test sensitivity). |
T13 | 1403-1468 | Sentence | denotes | The median duration of time for IgG seroconversion was 11.5 days. |
T14 | 1469-1601 | Sentence | denotes | During the convalescent phase of the infection, a decline in the IgG level was observed in patients who were followed for >100 days. |
T15 | 1602-1710 | Sentence | denotes | Despite that decline, 92.3 % of the patient cohort remained IgG positive 3-6 months following symptom onset. |
T16 | 1711-1723 | Sentence | denotes | CONCLUSIONS: |
T17 | 1724-1907 | Sentence | denotes | This study demonstrates the Abbott IgM assay against SARS-CoV-2 is detected slightly earlier compared to IgG, with both tests exhibiting excellent overall sensitivity and specificity. |
T18 | 1908-2064 | Sentence | denotes | In symptomatic patients who test negative by PCR for a SARS-CoV-2 infection, assessing IgM and IgG antibodies can aid in supporting a diagnosis of COVID-19. |